# BENEPALI™ (etanercept)
Keywords: BENEPALI, etanercept, anti-TNF therapy, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, juvenile idiopathic arthritis, biosimilar, immunology

> This page provides detailed information about BENEPALI™, a biosimilar anti-TNF therapy used for treating various autoimmune conditions in adults and pediatric patients. It includes indications, mechanism of action, patient profiles, and resources for healthcare professionals.

## Details
- [Indication](#): BENEPALI™ is indicated for treating autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and juvenile idiopathic arthritis in specific patient groups.
- [Mechanism of Action](#): Explains how BENEPALI™, an anti-TNF receptor fusion protein, inhibits TNF-α by acting as a decoy receptor.
- [Who Could Benefit from BENEPALI™?](#): Highlights examples of patients with rheumatoid arthritis who may benefit from BENEPALI™ based on their medical circumstances.
- [Resources](#): Provides materials to support healthcare professionals in discussing BENEPALI™ treatment with eligible patients.
- [Additional Resources](#): Includes on-demand podcasts and webinars about optimizing therapy and experiences with anti-TNF biosimilars.
- [Related Products](#): Mentions other biosimilar products such as FLIXABI™ (infliximab) and IMRALDI™ (adalimumab).
- [References](#): Lists sources and regulatory documents supporting the information about BENEPALI™.
- [Adverse Event Reporting](#): Details procedures for reporting adverse events in the UK and Ireland, including contact information for Biogen.